vs

Side-by-side financial comparison of Abbott Laboratories (ABT) and HEALTHCARE SERVICES GROUP INC (HCSG). Click either name above to swap in a different company.

Abbott Laboratories is the larger business by last-quarter revenue ($11.5B vs $466.7M, roughly 24.6× HEALTHCARE SERVICES GROUP INC). On growth, HEALTHCARE SERVICES GROUP INC posted the faster year-over-year revenue change (6.6% vs 4.4%). Abbott Laboratories produced more free cash flow last quarter ($2.6B vs $16.0M). Over the past eight quarters, Abbott Laboratories's revenue compounded faster (7.2% CAGR vs 5.0%).

Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.

Tenet Healthcare Corporation is an American for-profit multinational healthcare services company based in Dallas. Through its brands, subsidiaries, joint ventures, and partnerships including United Surgical Partners International (USPI), the company operates 65 hospitals and over 450 healthcare facilities. Tenet also runs Conifer Health Solutions, which provides healthcare support services to health systems and other clients.

ABT vs HCSG — Head-to-Head

Bigger by revenue
ABT
ABT
24.6× larger
ABT
$11.5B
$466.7M
HCSG
Growing faster (revenue YoY)
HCSG
HCSG
+2.2% gap
HCSG
6.6%
4.4%
ABT
More free cash flow
ABT
ABT
$2.6B more FCF
ABT
$2.6B
$16.0M
HCSG
Faster 2-yr revenue CAGR
ABT
ABT
Annualised
ABT
7.2%
5.0%
HCSG

Income Statement — Q4 2025 vs Q4 2025

Metric
ABT
ABT
HCSG
HCSG
Revenue
$11.5B
$466.7M
Net Profit
$1.8B
Gross Margin
57.0%
15.4%
Operating Margin
19.6%
6.1%
Net Margin
15.5%
Revenue YoY
4.4%
6.6%
Net Profit YoY
-80.8%
EPS (diluted)
$1.01
$0.43

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABT
ABT
HCSG
HCSG
Q4 25
$11.5B
$466.7M
Q3 25
$11.4B
$464.3M
Q2 25
$11.1B
$458.5M
Q1 25
$10.4B
$447.7M
Q4 24
$11.0B
$437.8M
Q3 24
$10.6B
$428.1M
Q2 24
$10.4B
$426.3M
Q1 24
$10.0B
$423.4M
Net Profit
ABT
ABT
HCSG
HCSG
Q4 25
$1.8B
Q3 25
$1.6B
$43.0M
Q2 25
$1.8B
$-32.4M
Q1 25
$1.3B
$17.2M
Q4 24
$9.2B
Q3 24
$1.6B
$14.0M
Q2 24
$1.3B
$-1.8M
Q1 24
$1.2B
$15.3M
Gross Margin
ABT
ABT
HCSG
HCSG
Q4 25
57.0%
15.4%
Q3 25
55.4%
20.8%
Q2 25
56.4%
0.6%
Q1 25
56.9%
15.2%
Q4 24
55.0%
13.4%
Q3 24
55.8%
14.8%
Q2 24
55.6%
9.7%
Q1 24
55.2%
15.2%
Operating Margin
ABT
ABT
HCSG
HCSG
Q4 25
19.6%
6.1%
Q3 25
18.1%
12.3%
Q2 25
18.4%
-9.1%
Q1 25
16.3%
5.3%
Q4 24
17.4%
3.4%
Q3 24
17.5%
4.4%
Q2 24
16.1%
-0.5%
Q1 24
13.9%
5.0%
Net Margin
ABT
ABT
HCSG
HCSG
Q4 25
15.5%
Q3 25
14.5%
9.3%
Q2 25
16.0%
-7.1%
Q1 25
12.8%
3.8%
Q4 24
84.1%
Q3 24
15.5%
3.3%
Q2 24
12.5%
-0.4%
Q1 24
12.3%
3.6%
EPS (diluted)
ABT
ABT
HCSG
HCSG
Q4 25
$1.01
$0.43
Q3 25
$0.94
$0.59
Q2 25
$1.01
$-0.44
Q1 25
$0.76
$0.23
Q4 24
$5.26
$0.15
Q3 24
$0.94
$0.19
Q2 24
$0.74
$-0.02
Q1 24
$0.70
$0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABT
ABT
HCSG
HCSG
Cash + ST InvestmentsLiquidity on hand
$8.9B
$168.0M
Total DebtLower is stronger
$12.9B
Stockholders' EquityBook value
$52.1B
$510.2M
Total Assets
$86.7B
$794.3M
Debt / EquityLower = less leverage
0.25×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABT
ABT
HCSG
HCSG
Q4 25
$8.9B
$168.0M
Q3 25
$7.7B
$177.5M
Q2 25
$7.3B
$134.5M
Q1 25
$6.8B
$114.8M
Q4 24
$8.0B
$107.3M
Q3 24
$7.8B
$103.8M
Q2 24
$7.2B
$105.6M
Q1 24
$6.7B
$104.9M
Total Debt
ABT
ABT
HCSG
HCSG
Q4 25
$12.9B
Q3 25
Q2 25
Q1 25
Q4 24
$14.1B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ABT
ABT
HCSG
HCSG
Q4 25
$52.1B
$510.2M
Q3 25
$51.0B
$496.0M
Q2 25
$50.6B
$477.0M
Q1 25
$48.8B
$514.2M
Q4 24
$47.7B
$499.9M
Q3 24
$39.8B
$488.7M
Q2 24
$39.3B
$471.4M
Q1 24
$38.8B
$474.6M
Total Assets
ABT
ABT
HCSG
HCSG
Q4 25
$86.7B
$794.3M
Q3 25
$84.2B
$804.3M
Q2 25
$84.0B
$802.2M
Q1 25
$81.4B
$823.0M
Q4 24
$81.4B
$802.8M
Q3 24
$74.4B
$805.8M
Q2 24
$73.0B
$799.7M
Q1 24
$72.5B
$803.9M
Debt / Equity
ABT
ABT
HCSG
HCSG
Q4 25
0.25×
Q3 25
Q2 25
Q1 25
Q4 24
0.30×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABT
ABT
HCSG
HCSG
Operating Cash FlowLast quarter
$3.3B
$17.4M
Free Cash FlowOCF − Capex
$2.6B
$16.0M
FCF MarginFCF / Revenue
22.9%
3.4%
Capex IntensityCapex / Revenue
6.0%
0.3%
Cash ConversionOCF / Net Profit
1.87×
TTM Free Cash FlowTrailing 4 quarters
$7.4B
$139.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABT
ABT
HCSG
HCSG
Q4 25
$3.3B
$17.4M
Q3 25
$2.8B
$71.3M
Q2 25
$2.0B
$28.8M
Q1 25
$1.4B
$27.5M
Q4 24
$2.9B
$36.2M
Q3 24
$2.7B
$4.3M
Q2 24
$2.0B
$16.3M
Q1 24
$1.0B
$-26.0M
Free Cash Flow
ABT
ABT
HCSG
HCSG
Q4 25
$2.6B
$16.0M
Q3 25
$2.3B
$70.0M
Q2 25
$1.5B
$27.4M
Q1 25
$933.0M
$25.8M
Q4 24
$2.1B
$34.8M
Q3 24
$2.1B
$2.9M
Q2 24
$1.4B
$15.0M
Q1 24
$627.0M
$-28.2M
FCF Margin
ABT
ABT
HCSG
HCSG
Q4 25
22.9%
3.4%
Q3 25
20.2%
15.1%
Q2 25
13.9%
6.0%
Q1 25
9.0%
5.8%
Q4 24
19.6%
7.9%
Q3 24
20.2%
0.7%
Q2 24
13.8%
3.5%
Q1 24
6.3%
-6.7%
Capex Intensity
ABT
ABT
HCSG
HCSG
Q4 25
6.0%
0.3%
Q3 25
4.4%
0.3%
Q2 25
4.5%
0.3%
Q1 25
4.7%
0.4%
Q4 24
6.6%
0.3%
Q3 24
5.2%
0.3%
Q2 24
5.1%
0.3%
Q1 24
4.0%
0.5%
Cash Conversion
ABT
ABT
HCSG
HCSG
Q4 25
1.87×
Q3 25
1.70×
1.66×
Q2 25
1.15×
Q1 25
1.07×
1.60×
Q4 24
0.31×
Q3 24
1.64×
0.31×
Q2 24
1.51×
Q1 24
0.84×
-1.70×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons